Log In Sign up
The largest database of trusted experimental protocols
> Chemicals & Drugs > Organic Chemical > Dipyridamole

Dipyridamole

Dipyridamole is a medication primarily used to prevent blood clots and treat certain heart conditions.
This AI-powered platform from PubCompare.ai can help optimize your Dipyridamole research protocols by locating the best approaches from scientific literature, preprints, and patents.
Compare protocols side-by-side using the platform's AI analysis to identify the most reproducible and effective methods.
Streamline your research and improve your outcomes with the comprehensive search tools and insights provided by PubCompare.ai.
Discover how this innovative solution can enhance your Dipyridamole studies today.

Most cited protocols related to «Dipyridamole»

1
Thromboembolism Risk in Non-Valvular Atrial Fibrillation
Cited 24 times
In patients discharged with non-valvular atrial fibrillation who were not receiving treatment with vitamin K antagonists or heparins, we estimated event rates for thromboembolism and death for the various CHADS2 and CHA2DS2-VASc scores and for the specific covariate combinations forming the scores of 1 or 2. We estimated the risk of thromboembolism by using Cox proportional hazard regression models. In the Cox models, we analysed the risk associated with all possible risk factor combinations for CHADS2 score=1 (four combinations) and CHADS2 score=2 (seven combinations); we used CHADS2 score=0 as the reference. In the same manner, other Cox models analysed the risk associated with all possible risk factor combinations for CHA2DS2-VASc score=1 (six combinations) and CHA2DS2-VASc score=2 (17 combinations), with CHA2DS2-VASc score=0 used as the reference. We did all analyses for one, five, and 10 years of follow-up. In additional Cox regression models, we included concomitant treatment with antiplatelet drugs (that is, primary acetylsalicylic acid, clopidogrel, and dipyridamole), to adjust for this potential confounder. We also did sensitivity analyses by not including pulmonary embolism as an outcome.
We used C statistics estimated from Cox regression models to assess the predictive capability of CHADS2 and CHA2DS2-VASc for thromboembolism, using the method described by Liu and colleagues.24 C statistics give a measure of how well the risk prediction scheme identifies patients who will have a future event. For estimating C statistics, we analysed CHADS2 and CHA2DS2-VASc as risk scores (0-6 and 0-9) and as risk groups (low, intermediate, and high). We also evaluated the scores both as categorical and as continuous covariates. We constructed survival curves, based on Kaplan-Meier estimates of the probability of remaining free of thromboembolism with a score of 0 and 1, for the two risk stratification schemes. We considered a two sided P value <0.05 to be statistically significant. In all Cox models, the model assumptions (that is, proportional hazards, linearity of continuous covariates, and lack of interactions) were found to be valid. We used SAS statistical software version 9.1 and Stata statistical software version 11.0 for the analyses.
Olesen J.B., Lip G.Y., Hansen M.L., Hansen P.R., Tolstrup J.S., Lindhardsen J., Selmer C., Ahlehoff O., Olsen A.M., Gislason G.H, & Torp-Pedersen C. (2011). Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. The BMJ, 342, d124.
Publication 2011
antagonists Antiplatelet Agents Aspirin Atrial Fibrillation Clopidogrel Dipyridamole Heparin Hypersensitivity Patients Population at Risk Pulmonary Embolism Thromboembolism Vitamin K
2
Reproducibility of Cardiac 82Rb PET Imaging
Cited 19 times
Twenty-two subjects (11 women and 11 men) were included in the reproducibility study and consisted of 19 healthy volunteers and 3 patients with evidence of coronary artery disease (CAD). All subjects were admitted twice to the Nuclear Medicine Division of the Radiology Department at the Brigham and Women's Hospital within a two-week interval and underwent repeated rest/stress studies. At each visit, they were injected with 50 mCi of 82Rb and imaged dynamically for 6 minutes at rest and during dipyridamole stress (IV infusion of 0.142 mg/kg/min for 4 min, max 60 mg). Following an overnight fast and a 24-hour cessation of all caffeine- or methylxanthine-containing substances, subjects were scanned in 2D mode on a whole body PET-CT scanner with BGO detectors (Discovery ST Lightspeed 64, General Electric Healthcare, Milwaukee, WI). First, a scout CT acquisition (120 kVp, 10 mA) was performed to ensure proper patient positioning, then a CT transmission scan was acquired (140 kVp, 20 mA) for subsequent attenuation correction. Beginning at the time of intravenous (i.v.) bolus administration of 50 mCi (1850 MBq) of 82Rb (Bracco Diagnostics, Princeton, NJ) in 14±6 mL of saline, twenty seven dynamic PET frames were acquired over six minutes as follows: fourteen 5-sec acquisitions were first performed, followed by six 10-sec acquisitions, three 20-sec acquisitions, three 30-sec acquisitions and finally, one 90-sec acquisition. The initial fast frames were used to capture the rapid wash-in and wash-out of 82Rb from the left and right ventricular cavities. Immediately after completion of the rest study, a standard i.v. dipyridamole infusion (0.142 mg/kg/min) was performed for 4 minutes. Three minutes after termination of the dipyridamole infusion, a second dose of 50 mCi (1850 MBq) of 82Rb was injected and dynamic PET frames acquired in the same fashion. A second CT transmission scan (140 kVp, 20 mA) was then acquired for attenuation correction of the stress images. The heart rate, systemic blood pressure, and 12-lead ECG were recorded at baseline and throughout the infusion of dipyridamole. The rate pressure product was calculated as heart rate multiplied by systolic blood pressure. Hemodynamic data are summarized in Table 1.
, & Fakhri G.E. (2009). Reproducibility and Accuracy of Quantitative Myocardial Blood Flow Using 82Rb-PET: Comparison with 13N-Ammonia. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 50(7), 1062-1071.
Publication 2009
Caffeine CAT SCANNERS X RAY Coronary Artery Disease Dental Caries Diagnosis Dipyridamole Electricity Electrocardiography, 12-Lead Healthy Volunteers Hemodynamics Human Body Intravenous Infusion methylxanthine Patients Pressure Rate, Heart Reading Frames Saline Solution Systolic Pressure Transmission, Communicable Disease Ventricles, Right Woman X-Ray Computed Tomography
3
Cardiac PET/CT Imaging with 82Rb
Cited 7 times
All 82Rb PET/CT (Discovery Rx; GE Healthcare) acquisitions were performed in 2-dimensional mode. The 76.38-s half-life of 82Rb and the corresponding requirement for pharmacologic vasodilation require that image acquisition be completed within 10 min of the 82Rb infusion. The following protocol was used to collect the pharmacokinetic data needed for dosimetry while remaining within the required constraints. First, a whole-body transmission CT scan (120 kVp; 20–200 mA, automatically adjusted; pitch, 0.5; and rotation time, 0.5 s) was obtained. A series of 3 whole-body PET scans was subsequently acquired after an infusion of 1,534 ± 118 MBq of 82Rb at rest. Stress was induced by administration of the vasodilator, dipyridamole. Four minutes after a 4-min infusion of dipyridamole (0.56 mg/kg), about 1,502 ± 158 MBq of 82Rb were infused and 3 serial whole-body PET scans were acquired. The heart rate, blood pressure, and electrocardiogram were monitored continuously throughout pharmacologic vasodilation. Each whole-body PET scan was obtained with a maximum of six 20-s bed positions starting at the level of the femurs and extending to the base of the skull. The 3 serially collected whole-body PET scans were completed in approximately 9 min. The mean infusion time for the 82Rb activity from the 82Sr/82Rb generator was 25 s (range, 18–32 s). The first scan was started from the base of the femurs 10 s after the end of 82Rb infusion. Attenuation-corrected whole-body PET images were reconstructed for subsequent region-of-interest analysis.
Senthamizhchelvan S., Bravo P.E., Lodge M.A., Merrill J., Bengel F.M, & Sgouros G. (2011). Radiation Dosimetry of 82Rb in Humans Under Pharmacologic Stress. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 52(3), 485-491.
Publication 2011
Base of Skull Blood Pressure Body Image Dipyridamole Electrocardiography Femur Radiometry Radionuclide Imaging Rate, Heart Scan, CT PET Transmission, Communicable Disease Vasodilation Vasodilator Agents Whole Body Imaging
4
Quantifying Myocardial Blood Flow with Rubidium-82 PET
Cited 6 times
Patients were studied with a whole-body PET–computed tomography scanner (Discovery RX or STE LightSpeed 64, GE Healthcare, Milwaukee, WI) in 2D mode using 1480–2200 MBq of 82Rubidium as a flow tracer at rest and stress as has been previously described.13 (link) Maximal coronary vasodilation was achieved using dipyridamole (N=584), adenosine (N=96), regadenoson (N=482) or dobutamine (N=56), as clinically appropriate. PET images were evaluated semi-quantitatively to identify obstructive CAD.14 (link) Scans with summed stress score <3 were considered normal. Hybrid factor analysis15 with a two-compartment tracer kinetic model and well-validated extraction model for 82Rubidium16 (link) were used to quantify absolute myocardial blood flow (MBF) in ml/min/g of tissue and coronary flow reserve (CFR; stress/rest MBF). Corrected CFR, was computed by dividing the stress MBF by the corrected rest MBF, which accounts for differences in resting cardiac work (rest MBF / [rest heart rate * rest systolic blood pressure]) multiplied by 10,000).
Murthy V.L., Naya M., Taqueti V.R., Foster C.R., Gaber M., Hainer J., Dorbala S., Blankstein R., Rimoldi O., Camici P.G, & Di Carli M.F. (2014). Effects of Gender on Coronary Microvascular Dysfunction and Cardiac Outcomes. Circulation, 129(24), 2518-2527.
Publication 2014
Adenosine Blood Circulation CAT SCANNERS X RAY Dipyridamole Dobutamine factor A Heart Human Body Hybrids Kinetics Myocardium Patients Radionuclide Imaging Rate, Heart regadenoson Systolic Pressure Vasodilation
5
Antiplatelet Comparison in Ischemic Stroke
Cited 6 times
The Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial was a 2-by-2 factorial, double-blind, active and placebo-controlled study of the fixed combination of low-dose aspirin (25 mg) and extended-release dipyridamole (200 mg) given twice daily as compared with clopid ogrel (75 mg) given once daily, and of telmisartan (80 mg once daily) as compared with placebo, in patients with a recent ischemic stroke. This article focuses on the antiplatelet comparison within the factorial design. The antiplatelet part of the factorial design was initially intended to compare clopidogrel plus aspirin with aspirin plus extended-release dipyridamole. The design was modified, after 2027 patients were randomly assigned, when the Management of Atherothrombosis with Clopidogrel in High-Risk Patients with Recent TIA or Ischemic Stroke (MATCH) trial demonstrated an increased risk of bleeding with the combination of clopidogrel and aspirin.8 (link) Patients initially assigned to receive clopidogrel plus aspirin had been treated for up to 8 months before they were switched to clopidogrel alone at the time of the protocol amendment; 18,305 patients were subsequently randomly assigned to receive aspirin plus extended-release dipyridamole or clopidogrel alone.
Details of the trial design have been published previously.18 (link) The steering committee designed and oversaw the trial; data management was performed by the sponsor (Boehringer Ingelheim). A trial management committee, with representatives from the steering committee and the sponsor, met regularly to evaluate progress. The cochairs and the members of the steering committee had complete access to the trial data and prepared the final manuscript, and they vouch for the design, the final statistical analysis, and the completeness, accuracy, and interpretation of the data. The final statistical analyses were conducted simultaneously by the independent statisticians at the Medical University of South Carolina (who provided data and interim analysis reports to the data and safety monitoring committee) and the statisticians from Boehringer Ingelheim.
The protocol was approved by the appropriate regulatory authorities and ethics committees or institutional review boards. All patients provided written informed consent.
Sacco R.L., Diener H.C., Yusuf S., Cotton D., Ôunpuu S., Lawton W.A., Palesch Y., Martin R.H., Albers G.W., Bath P., Bornstein N., Chan B.P., Chen S.T., Cunha L., Dahlöf B., De Keyser J., Donnan G.A., Estol C., Gorelick P., Gu V., Hermansson K., Hilbrich L., Kaste M., Lu C., Machnig T., Pais P., Roberts R., Skvortsova V., Teal P., Toni D., VanderMaelen C., Voigt T., Weber M, & Yoon B.W. (2008). Aspirin and Extended-Release Dipyridamole versus Clopidogrel for Recurrent Stroke. The New England journal of medicine, 359(12), 1238-1251.
Publication 2008
Aspirin Aspirin, Dipyridamole Drug Combination Cerebrovascular Accident Clopidogrel Committee Members Dipyridamole Ethics Committees Ethics Committees, Research Extended-Release Dipyridamole-Aspirin Patients Placebos Safety Secondary Prevention Stroke, Ischemic Telmisartan Treatment Protocols

Most recents protocols related to «Dipyridamole»

1
Dipyridamole Reverses DHEA-Induced Hyperandrogenism in Mice

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2023
Animals Biological Assay Biotin Body Weight Corn oil Dehydroepiandrosterone Sulfate Diestrus Dipyridamole Eosin Ethanol Ethyl Ether Freezing Gonadal Steroid Hormones Granulosa Cell Hormones Hyperandrogenism Immunohistochemistry Joint Dislocations Mus Neck Ovary Paraffin Embedding paraform Phenotype Prasterone Serum Sesame Oil Sulfoxide, Dimethyl Tissues
2
Estrous Cycle Analysis by Vaginal Smears

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2023
Aftercare Cells Diestrus Dipyridamole Epithelial Cells Estrus Leukocytes Metestrus Microscopy Proestrus Squamous Epithelial Cells Vaginal Smears
3
Astragalus Formula for Immunosuppressive Therapy
All participants received routine therapies according to clinical practice guidelines. Conventional therapy includes more rest, low salt, low fat, high quality and protein diet; drugs aimed to correct dyslipidaemia (e.g., statins), antialdosterone drugs (e.g., spironolactone), antihypertensive (e.g., ACEi or ARB), antithrombotic agents (e.g., dipyridamole).
Treatment group participants needed to have received oral Astragalus formula (decoction, pill, powder, or capsule) in combination with immunosuppressive therapy.
Control group participants received immunosuppressive therapy.
Huangqi serves as a principal medicine, defined as follows: the properties of Huangqi are consistent with the main aims of the formula.
Wang D., Wang L., Zhang M., Li P., Zhang Q, & Bao K. (2023). Astragalus membranaceus formula for moderate-high risk idiopathic membranous nephropathy: A meta-analysis. Medicine, 102(9), e32918.
Full text: Click here
Publication 2023
Antihypertensive Agents Antithrombotic Agents Capsule Combined Modality Therapy Contraceptives, Oral Dipyridamole Dyslipidemias Fat-Restricted Diet Huang Qi Hydroxymethylglutaryl-CoA Reductase Inhibitors Immunosuppression Immunosuppressive Agents Pharmaceutical Preparations Powder Proteins Sodium Chloride, Dietary Spironolactone Talus Therapy, Diet
4
Dipyridamole, Valsartan, and Methylprednisolone with Huangkui Capsules
Patients in both groups received 30 mg of dipyridamole tablets (National Drug Administration: H20066585) thrice daily, 90 mg of valsartan capsules (National Drug Administration: H20010811) daily, and 45 mg of methylprednisolone tablets (National Drug Administration: H2220245) daily as an initial dose and 8 mg daily as a maintenance dose. All the above-given drugs were administered orally, and the duration of treatment was 10 weeks.
Patients in the experimental group additionally received 2 g of Huangkui capsules (National Drug Administration: Z19990040) thrice daily. The duration of treatment was 10 weeks.
Yuan L., Cai K, & Zou Y. (2023). Clinical Efficacy of Huangkui Capsule Plus Methylprednisolone for Immunoglobulin A Nephropathy and Its Effect on Renal Function and Serum Inflammatory Factors. Evidence-based Complementary and Alternative Medicine : eCAM, 2023, 3020033.
Full text: Click here
Publication 2023
Capsule Dipyridamole Huangkui Methylprednisolone Patients Pharmaceutical Preparations Valsartan
5
Dual Antiplatelet Therapy in ACS Patients
The study cohort has been described previously [21 (link)]. In total, 206 ACS patients on daily aspirin (100 mg/day), and either prasugrel (10 mg/d, n = 116) or ticagrelor (180 mg/d, n = 90), were included. Pre- and periprocedurally, all patients received weight-adjusted unfractionated heparin (UFH) (70–100 IU/kg, aiming for an activated clotting time > 250 s) [22 (link)]. None of the patients received a GPIIb/IIIa inhibitor. After successful PCI, blood was drawn after an overnight fast. Exclusion criteria included oral anticoagulation with either vitamin K antagonists (warfarin, phenprocoumon and acenocoumarol) or direct oral anticoagulants (edoxaban, dabigatran, apixaban and rivaroxaban), a known aspirin, prasugrel or ticagrelor intolerance (allergic reaction and gastrointestinal bleeding complication), a history of bleeding complications or a positive family history of bleeding complications, treatment with ticlopidine, dipyridamole or nonsteroidal antirheumatic drugs, malignant myeloproliferative disorders or heparin-induced thrombocytopenia, major surgery within one week before enrollment, severe hepatic failure with impaired hepatic synthesis (spontaneous international normalized ratio [INR] ≥1.5 and albumin levels <35 mg/dl) [23 (link)], known qualitative defects in platelet function, a platelet count < 100.000 or > 450.000/µL and a hematocrit < 30%.
The study protocol was in accordance with the criteria of the Declaration of Helsinki and has been approved by the Ethics Committee of the Medical University of Vienna (EC-No. 1940/2013). All study participants gave written informed consent.
Mutschlechner D., Tscharre M., Wadowski P.P., Pultar J., Weikert C., Lee S., Eichelberger B., Panzer S., Perkmann T, & Gremmel T. (2023). Growth Differentiation Factor 15 Is Associated with Platelet Reactivity in Patients with Acute Coronary Syndrome. Journal of Clinical Medicine, 12(4), 1627.
Full text: Click here
Publication 2023
Acenocoumarol Albumins Allergic Reaction Anabolism antagonists Anticoagulants Antirheumatic Agents apixaban Aspirin BLOOD Dabigatran Dipyridamole edoxaban Ethics Committees Heparin International Normalized Ratio Liver Failure Myeloproliferative Disorders Operative Surgical Procedures Patients Phenprocoumon Platelet Aggregation Platelet Counts, Blood Platelet Glycoprotein GPIIb-IIIa Complex Prasugrel Rivaroxaban Thrombocytopenia Ticagrelor Ticlopidine Vitamin K Volumes, Packed Erythrocyte Warfarin

Top products related to «Dipyridamole»

1
Dipyridamole by Merck Group
Sourced in United States, United Kingdom, Germany, Switzerland, Australia
Dipyridamole is a laboratory reagent used for various applications in research and analysis. It functions as an inhibitor of platelet aggregation and as an anti-thrombotic agent. The core function of Dipyridamole is to prevent the formation of blood clots and promote blood flow.
2
Adenosine by Merck Group
Sourced in United States, Germany, United Kingdom, China, Sao Tome and Principe, France, Italy, Austria, Canada, Japan, Switzerland
Adenosine is a laboratory chemical used for various research and analytical applications. It is a naturally occurring nucleoside composed of adenine and ribose. Adenosine plays a role in cellular energy transfer and signaling processes. Due to its versatile properties, Adenosine is a widely used compound in many scientific fields.
3
Discovery rx by GE Healthcare
Sourced in United States
The Discovery RX is a laboratory equipment product offered by GE Healthcare. It is designed to perform basic analytical tasks in a clinical laboratory setting. The core function of the Discovery RX is to enable reliable and efficient data collection and analysis for researchers and healthcare professionals.
4
Ste lightspeed 64 by GE Healthcare
Sourced in United States
The STE LightSpeed 64 is a computed tomography (CT) scanner developed by GE Healthcare. It is designed to perform high-speed, high-resolution imaging of the body's internal structures. The system utilizes a 64-slice detector configuration to capture multiple slices of data simultaneously, enabling rapid image acquisition and reconstruction.
5
Fetal bovine serum (fbs) by Thermo Fisher Scientific
Sourced in United States, China, United Kingdom, Germany, Australia, Japan, Canada, Italy, France, Switzerland, New Zealand, Brazil, Belgium, India, Spain, Israel, Austria, Poland, Ireland, Sweden, Macao, Netherlands, Denmark, Cameroon, Singapore, Portugal, Argentina, Holy See (Vatican City State), Morocco, Uruguay, Mexico, Thailand, Sao Tome and Principe, Hungary, Panama, Hong Kong, Norway, United Arab Emirates, Czechia, Russian Federation, Chile, Moldova, Republic of, Gabon, Palestine, State of, Saudi Arabia, Senegal
Fetal Bovine Serum (FBS) is a cell culture supplement derived from the blood of bovine fetuses. FBS provides a source of proteins, growth factors, and other components that support the growth and maintenance of various cell types in in vitro cell culture applications.
6
Uridine by Merck Group
Sourced in United States, Germany, China, United Kingdom, France, Japan, Sao Tome and Principe
Uridine is a nucleoside that is a constituent of ribonucleic acid (RNA). It serves as a precursor in the biosynthesis of uridine triphosphate (UTP) and other pyrimidine nucleotides. Uridine can be used as a research tool in various biological and biochemical applications.
7
Discovery nm 530c by GE Healthcare
Sourced in United States, Israel
The Discovery NM 530c is a nuclear imaging system designed for single-photon emission computed tomography (SPECT) and planar imaging. It is capable of acquiring and processing high-quality images for diagnostic purposes. The system utilizes advanced technology to provide reliable and accurate results for healthcare professionals.
8
β estradiol by Merck Group
Sourced in United States, Germany, Macao, China, Sao Tome and Principe, United Kingdom, Japan
β-estradiol is a chemical compound that is commonly used as a laboratory reagent. It is the primary female sex hormone and plays a crucial role in the regulation of the reproductive cycle. β-estradiol is a naturally occurring estrogen and is widely used in various research applications, including cell culture studies and experiments related to reproductive biology.
9
Dipyridamole dipy by Merck Group
Sourced in United States
Dipyridamole (DIPY) is a laboratory reagent used in research applications. It is a pyridine-based compound that functions as a phosphodiesterase inhibitor. DIPY is commonly used in studies involving platelet aggregation and vascular function.
10
Penicillin streptomycin by Thermo Fisher Scientific
Sourced in United States, Germany, United Kingdom, China, Canada, France, Japan, Australia, Switzerland, Israel, Italy, Belgium, Austria, Spain, Gabon, Ireland, New Zealand, Sweden, Netherlands, Denmark, Brazil, Macao, India, Singapore, Poland, Argentina, Cameroon, Uruguay, Morocco, Panama, Colombia, Holy See (Vatican City State), Hungary, Norway, Portugal, Mexico, Thailand, Palestine, State of, Finland, Moldova, Republic of, Jamaica, Czechia
Penicillin/streptomycin is a commonly used antibiotic solution for cell culture applications. It contains a combination of penicillin and streptomycin, which are broad-spectrum antibiotics that inhibit the growth of both Gram-positive and Gram-negative bacteria.

More about "Dipyridamole"

Dipyridamole is a versatile medication primarily used to prevent blood clots and treat certain heart conditions.
This anti-platelet agent, also known as DIPY, works by inhibiting the uptake of adenosine, a natural substance in the body that plays a crucial role in regulating blood flow and preventing clot formation.
Beyond its primary applications, Dipyridamole has been explored for its potential therapeutic benefits in various other medical conditions.
Researchers have investigated its use in improving cerebrovascular function, reducing the risk of stroke, and managing certain neurological disorders.
The development of Dipyridamole was a significant milestone in the field of cardiovascular pharmacology.
Its discovery and subsequent optimzation of research protocols have been facilitated by innovative platforms like PubCompare.ai, which leverage artificial intelligence to analyze and compare scientific literature, preprints, and patents.
This AI-powered tool can help researchers identify the most reproducible and effective methods for Dipyridamole studies, streamlining the research process and enhancing outcomes.
In addition to Dipyridamole, other related compounds like Adenosine, Uridine, and β-estradiol have been studied for their potential therapeutic applications.
Researchers have also explored the use of Dipyridamole in combination with other medications, such as Penicillin/streptomycin, to investigate synergistic effects or improve treatment efficacy.
The versatility of Dipyridamole and the availability of advanced research tools like PubCompare.ai have opened up new avenues for exploring its clinical potential.
By optimizing research protocols and leveraging the latest scientific insights, researchers can contribute to the ongoing development of this important pharmaceutical agent and its applications in various medical fields.